Tailoring controlled ovarian hyperstimulation (COH) to the individual patient can be challenging because the ovarian response varies substantially between patients. Pharmacogenetics has emerged as a new area of research to improve the balance between desired and undesired actions of drugs based upon the genetic predisposition of the individual patient. Clinical studies demonstrated that the p.N680S polymorphism of the FSH receptor gene determines the ovarian response to FSH stimulation in patients undergoing in vitro fertilisation. In homozygous Ser680/Ser680 type women the FSH receptor appears to be more resistant to FSH action even in normal menstrual cycles. Therefore, genotyping of patients scheduled for COH could be an attractive tool to individualise FSH dosing according to genetic differences in ovarian sensitivity. More clinical studies are warranted to investigate genotyping for the p.N680S polymorphism as a routine diagnostic test before COH.

Pharmakogenetik bei der ovariellen stimulationstherapie / Greb, R. R.; Behre, H. M.; Simoni, M.. - In: JOURNAL FÜR REPRODUKTIONSMEDIZIN UND ENDOKRINOLOGIE. - ISSN 1810-2107. - 2:5(2005), pp. 281-290.

Pharmakogenetik bei der ovariellen stimulationstherapie

Simoni, M.
2005

Abstract

Tailoring controlled ovarian hyperstimulation (COH) to the individual patient can be challenging because the ovarian response varies substantially between patients. Pharmacogenetics has emerged as a new area of research to improve the balance between desired and undesired actions of drugs based upon the genetic predisposition of the individual patient. Clinical studies demonstrated that the p.N680S polymorphism of the FSH receptor gene determines the ovarian response to FSH stimulation in patients undergoing in vitro fertilisation. In homozygous Ser680/Ser680 type women the FSH receptor appears to be more resistant to FSH action even in normal menstrual cycles. Therefore, genotyping of patients scheduled for COH could be an attractive tool to individualise FSH dosing according to genetic differences in ovarian sensitivity. More clinical studies are warranted to investigate genotyping for the p.N680S polymorphism as a routine diagnostic test before COH.
2005
2
5
281
290
Pharmakogenetik bei der ovariellen stimulationstherapie / Greb, R. R.; Behre, H. M.; Simoni, M.. - In: JOURNAL FÜR REPRODUKTIONSMEDIZIN UND ENDOKRINOLOGIE. - ISSN 1810-2107. - 2:5(2005), pp. 281-290.
Greb, R. R.; Behre, H. M.; Simoni, M.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1165690
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact